6.恒生创新药指数; 7.恒生港股通创新药指数; 8.恒生港股通创新药精选指数;及 智通财经APP讯，药捷安康-B(02617)发布公告，根据恒生指数有限公司于2025年8月22日公布的恒生指 数系列季度检讨结果，公司已获选并将纳入包括但不限于下述恒生指数系列成份股，自2025年9月8日起 生效： 1.恒生综合指数; 2.恒生综合行业指数-医疗保健业; 3.恒生综合中小型股指数; 4.恒生综合小型股指数; 5.恒生医疗保健指数; 9.恒生港股通药品及生物技术(可投资)指数。 公告称，公司获纳入恒生综合指数及上述指数反映投资者的认可度上升。 ...

Core Viewpoint - The company Yunzhisheng (09678) has been selected to be included in various Hang Seng Index series, effective from September 8, 2025, which is expected to enhance its investment value and reputation in the capital market [1]. Group 1 - The company will be included in the following Hang Seng Index series: 1. Hang Seng Composite Index; 2. Hang Seng Composite Industry Index - Information Technology; 3. Hang Seng Composite Small Cap Index; 4. Hang Seng Composite Micro Cap Index; 5. Hang Seng Internet Technology Index; 6. Hang Seng Information Technology Index; 7. Hang Seng Information Technology (Investable) Index; 8. Hang Seng Hong Kong Stock Connect Information Technology Index; 9. Hang Seng Hong Kong Stock Connect Software and Semiconductor (Investable) Index; 10. Hang Seng Hong Kong Stock Connect Software and Semiconductor Index [1]. - The Hang Seng Index series is widely referenced and reflects the performance of the Hong Kong stock market [1]. - The board believes that inclusion in the Hang Seng Composite Index will help expand the shareholder base [1].

Core Viewpoint - The company, Baize Medical (02609), has been selected to be included in various Hang Seng Index series components effective from September 8, 2025, reflecting increased investor recognition of its operational performance and growth potential [1] Group 1: Index Inclusion - Baize Medical will be included in the Hang Seng Composite Index, Hang Seng Composite Industry Index - Healthcare, Hang Seng Composite Small Cap Index, Hang Seng Healthcare Index, and other related indices [1] - The Hang Seng Composite Index covers the top 95% of total market capitalization of companies listed on the Hong Kong Stock Exchange, serving as a comprehensive market benchmark [1] Group 2: Market Impact - Inclusion in the Hang Seng Composite Index will qualify the company's shares for trading through the Hong Kong Stock Connect programs, enhancing accessibility for mainland Chinese investors [1] - The board anticipates that this inclusion will increase the company's visibility in the capital markets, improve trading liquidity, and further enhance its investment value [1]

Core Viewpoint - The company, Baize Medical (02609), has been selected to be included in various Hang Seng Index series, effective from September 8, 2025, reflecting increased investor recognition of its operational performance and growth potential [1] Group 1: Inclusion in Hang Seng Index - Baize Medical will be included in the Hang Seng Composite Index, Hang Seng Composite Industry Index - Healthcare, Hang Seng Composite Small Cap Index, Hang Seng Healthcare Index, and other related indices [1] - The Hang Seng Composite Index covers the top 95% of total market capitalization of companies listed on the Hong Kong Stock Exchange, serving as a comprehensive market benchmark [1] Group 2: Impact on Market Presence - Inclusion in the Hang Seng Composite Index will qualify the company's shares for trading through the Hong Kong Stock Connect programs, enhancing accessibility for mainland Chinese investors [1] - The board anticipates that this inclusion will increase the company's visibility in the capital markets, improve trading liquidity, and further enhance its investment value [1]